Saudi Arabia to set up region's first cancer database
December 14, 2019

Saudi Arabia has become the first Middle East country to launch a new initiative in the effective management of cancer treatment with the establishment of a ‘Saudi Oncology Health Economics Expert Group’ (Sharp).

The Saudi Society of Clinical Pharmacy (SSCP) and AstraZeneca Saudi Arabia have signed"...

Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019
December 12, 2019

Octapharma has announced today that the final results from the NuProtect study, the largest prospective study of a single factor VIII (FVIII) product in true PUPs with severe haemophilia A, were presented today in an oral presentation at the American Society of Hematology (ASH) 2019 Annual Meeting in Orlando, Florida.

The NuProtect study was a prospective, multinational, open-label, non-controlled"...

70% Saudi citizens, residents satisfied with health care
December 11, 2019

RIYADH: Seventy percent of Saudi citizens have a positive outlook toward the Kingdom’s health services, according to a national survey.

And the competence of Saudi doctors and nurses was highest among the reasons for people being confident about the services provided by the country’s Ministry of Health.

The"...

Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 2019
December 11, 2019

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable......

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis
December 11, 2019

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01],......

Galderma Investigational Therapy Nemolizumab Granted FDA Breakthrough Therapy Designation for the Treatment of Patients Suffering from Prurigo Nodularis
December 9, 2019

Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis.

Prurigo nodularis is a rare, potentially debilitating, chronic skin condition with thick skin nodules covering large body areas and associated severe pruritus. It"...

Pharma manufacturing congress opens in Riyadh
December 5, 2019

The 5th Mena Pharmaceutical Manufacturing Congress and Exhibition kicked off today (Dec 4) at the Voco Hotel, Riyadh, shedding light on technological innovations, investment opportunities and developments in pharmaceutical manufacturing.

The three-day congress with the theme – ‘Improving pharmaceutical manufacturing through innovative strategies and knowledge’ – will discuss key innovations, challenges and opportunities in Saudi"...

UAE Ministry of Health Collaborates with Vocera to Improve Care Team Communication and Optimise Patient Safety
December 5, 2019

Vocera Communications, Inc. (NYSE:VCRA), a recognised leader in clinical communication and workflow solutions, today announced that the Ministry of Health and Prevention of the United Arab Emirates plans to standardise care team communication using Vocera technology. An expected enterprise-wide deployment of the Vocera smartphone app and the new Vocera Smartbadge is part of a strategic alignment aimed at improving care team collaboration, optimising operational efficiency, and elevating patient care and safety. “Our partnership with Vocera and the implementation of the company’s unique solutions represents a breakthrough in our digital transformation,” said Dr. Kalthoom Al Balooshi, Director of Hospitals Department, Ministry of Health and Prevention. “Initial installation of the......

SAVOLA launches two initiatives to empower people with disabilities
December 4, 2019

JEDDAH — As part of its efforts and commitment to empower disabled persons and enable them to play their role in the society and raise public awareness about disability issues, SAVOLA Group marked the International Day of Persons with Disabilities this year by honoring the champions of the Saudi national team for individuals with mental disabilities and launching two relevant initiatives.

The group organized a ceremony on this occasion attended"...

Al Rajhi REIT fund acquires 100-bed Saudi hospital
December 3, 2019

Al Rajhi Capital, one of the largest asset managers in Saudi Arabia and a leading regional investment firm, said its shari'a-compliant real estate investment trust (REIT) fund has acquired Al Salam NMC Hospital, a 100-bed multispecialty hospital located in the capital Riyadh, for SR164 million ($44 million).

The transaction was funded through the available shari'a-compliant debt facility for Al Rajhi REIT, said Al Rajhi Capital in its filing"...